Peptide-specific CTL induction in HBV-seropositive PBMC by stimulation with peptides in vitro: novel epitopes identified from chronic carriers.
Cytotoxic T lymphocytes (CTL) recognize and destroy virus-infected cells, and it has been established that epitope-based peptides could induce such CTL in vivo as well as in vitro. In this study attempts were made to define the epitopes that are recognized by the CTL, and thus a series of 9- to 10-mer peptides derived from the amino acid sequences of hepatitis B virus (HBV) proteins were synthesized on the basis of the previously described HLA-A2 peptide binding motif. The binding assay of the synthetic peptides using transporter-associated with antigen processing (TAP)-deficient human cell line, T2, showed that eight out of 11 peptides tested enhanced the expression of HLA-A2 molecules on the T2 cell surface. Some of these peptides triggered activation of CTL in peripheral blood mononuclear cells of HBV-seropositive chronic carriers. The activated CTL in turn recognized and killed the T2 cells pulsed with the same peptides. This study shows that novel HLA-A2-restricted epitopes exist in the natural repertoire of immunity against HBV. These findings can be useful in developing peptide-based therapeutics against viral infections.
Lee
H G
HG
Korea Research Institute of Bioscience and Biotechnology, Taejon, South Korea.
Lim
J S
JS
Lee
K Y
KY
Choi
Y K
YK
Choe
I S
IS
Chung
T W
TW
Kim
K
K
D002353:Carrier State / Q000097:blood / Q000276:immunology*; D002460:Cell Line; D002908:Chronic Disease; D003601:Cytotoxicity Tests, Immunologic; D000939:Epitopes / Q000276:immunology* / Q000302:isolation & purification; D015789:HLA-A2 Antigen / Q000276:immunology / Q000378:metabolism; D006509:Hepatitis B / Q000097:blood / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D006825:Hybridomas; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects*; D010455:Peptides / Q000276:immunology* / Q000302:isolation & purification / Q000494:pharmacology*; D010641:Phenotype; D011485:Protein Binding / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology*
D000939:Epitopes; D015789:HLA-A2 Antigen; D010455:Peptides